Serum-	serum-	O	O	O	O
and	and	O	O	O	O
glucocorticoid-inducible	glucocorticoid-inducible	O	O	O	O
kinase	kinase	O	O	O	O
1	1	O	O	O	O
in	in	O	O	O	O
doxorubicin-induced	doxorubicin-induced	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Doxorubicin-induced	doxorubicin-induced	O	O	O	O
nephropathy	nephropathy	O	DISEASE	OTHERS	I
leads	leads	O	O	O	O
to	to	O	O	O	O
epithelial	epithelial	O	O	O	O
sodium	sodium	CHEMICALS	O	OTHERS	I
channel	channel	O	O	O	O
(ENaC)-dependent	(enac)-dependent	O	O	O	O
volume	volume	O	O	OTHERS	I
retention	retention	O	O	OTHERS	I
and	and	O	O	O	O
renal	renal	O	O	O	O
fibrosis	fibrosis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
aldosterone-sensitive	aldosterone-sensitive	O	O	O	O
serum-	serum-	O	O	O	O
and	and	O	O	O	O
glucocorticoid-inducible	glucocorticoid-inducible	O	O	O	O
kinase	kinase	O	O	O	O
SGK1	sgk1	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
shown	shown	O	O	O	O
to	to	O	O	O	O
participate	participate	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
stimulation	stimulation	O	O	O	O
of	of	O	O	O	O
ENaC	enac	O	O	O	O
and	and	O	O	O	O
to	to	O	O	O	O
mediate	mediate	O	O	O	O
renal	renal	O	O	O	O
fibrosis	fibrosis	O	DISEASE	OTHERS	I
following	following	O	O	O	O
mineralocorticoid	mineralocorticoid	O	O	O	O
and	and	O	O	O	O
salt	salt	CHEMICALS	O	OTHERS	I
excess	excess	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
present	present	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
performed	performed	O	O	O	O
to	to	O	O	O	O
elucidate	elucidate	O	O	O	O
the	the	O	O	O	O
role	role	O	O	O	O
of	of	O	O	O	O
SGK1	sgk1	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
volume	volume	O	O	OTHERS	I
retention	retention	O	O	OTHERS	I
and	and	O	O	O	O
fibrosis	fibrosis	O	DISEASE	OTHERS	I
during	during	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

To	to	O	O	O	O
this	this	O	O	O	O
end	end	O	O	O	O
,	,	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
15	15	O	O	O	O
mug/g	mug/g	O	O	O	O
body	body	O	O	O	O
wt	wt	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
injected	injected	O	O	O	O
intravenously	intravenously	O	O	O	O
into	into	O	O	O	O
gene-targeted	gene-targeted	O	O	O	O
mice	mice	O	O	O	O
lacking	lacking	O	O	O	O
SGK1	sgk1	O	O	O	O
(	(	O	O	O	O
sgk1(-/-	sgk1(-/-	O	O	O	O
)	)	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
their	their	O	O	O	O
wild-type	wild-type	O	O	O	O
littermates	littermates	O	O	O	O
(	(	O	O	O	O
sgk1(+/+	sgk1(+/+	O	O	O	O
)	)	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
resulted	resulted	O	O	O	O
in	in	O	O	O	O
heavy	heavy	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
(	(	O	O	O	O
>	>	O	O	O	O
100	100	O	O	O	O
mg	mg	O	O	OTHERS	I
protein/mg	protein/mg	O	O	O	O
crea	crea	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
15/44	15/44	O	O	O	O
of	of	O	O	O	O
sgk1(+/+	sgk1(+/+	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
15/44	15/44	O	O	O	O
of	of	O	O	O	O
sgk1(-/-	sgk1(-/-	O	O	O	O
)	)	O	O	O	O
mice	mice	O	O	O	O
leading	leading	O	O	O	O
to	to	O	O	O	O
severe	severe	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
with	with	O	O	O	O
ascites	ascites	O	DISEASE	OTHERS	I
,	,	O	O	O	O
lipidemia	lipidemia	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
hypoalbuminemia	hypoalbuminemia	O	O	OTHERS	I
in	in	O	O	O	O
both	both	O	O	O	O
genotypes	genotypes	O	O	O	O
.	.	O	O	O	O

Plasma	plasma	O	O	O	O
aldosterone	aldosterone	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
increased	increased	O	O	O	O
in	in	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
mice	mice	O	O	O	O
of	of	O	O	O	O
both	both	O	O	O	O
genotypes	genotypes	O	O	O	O
and	and	O	O	O	O
was	was	O	O	O	O
followed	followed	O	O	O	O
by	by	O	O	O	O
increased	increased	O	O	O	O
SGK1	sgk1	O	O	O	O
protein	protein	O	O	O	O
expression	expression	O	O	O	O
in	in	O	O	O	O
sgk1(+/+	sgk1(+/+	O	O	O	O
)	)	O	O	O	O
mice	mice	O	O	O	O
.	.	O	O	O	O

Urinary	urinary	O	O	O	O
sodium	sodium	CHEMICALS	O	OTHERS	I
excretion	excretion	O	O	O	O
reached	reached	O	O	O	O
signficantly	signficantly	O	O	O	O
lower	lower	O	O	O	O
values	values	O	O	O	O
in	in	O	O	O	O
sgk1(+/+	sgk1(+/+	O	O	O	O
)	)	O	O	O	O
mice	mice	O	O	O	O
(	(	O	O	O	O
15	15	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
5	5	O	O	O	O
mumol/mg	mumol/mg	O	O	O	O
crea	crea	O	O	O	O
)	)	O	O	O	O
than	than	O	O	O	O
in	in	O	O	O	O
sgk1(-/-	sgk1(-/-	O	O	O	O
)	)	O	O	O	O
mice	mice	O	O	O	O
(	(	O	O	O	O
35	35	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
5	5	O	O	O	O
mumol/mg	mumol/mg	O	O	O	O
crea	crea	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
was	was	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
significantly	significantly	O	O	O	O
higher	higher	O	O	O	O
body	body	O	DISEASE	OTHERS	I
weight	weight	O	DISEASE	OTHERS	I
gain	gain	O	DISEASE	OTHERS	I
in	in	O	O	O	O
sgk1(+/+	sgk1(+/+	O	O	O	O
)	)	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
sgk1(-/-	sgk1(-/-	O	O	O	O
)	)	O	O	O	O
mice	mice	O	O	O	O
(	(	O	O	O	O
+	+	O	O	O	O
6.6	6.6	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.7	0.7	O	O	O	O
vs.	vs.	O	O	O	O
+	+	O	O	O	O
4.1	4.1	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.8	0.8	O	O	O	O
g	g	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

During	during	O	O	O	O
the	the	O	O	O	O
course	course	O	O	O	O
of	of	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
,	,	O	O	O	O
serum	serum	O	O	O	O
urea	urea	CHEMICALS	O	OTHERS	I
concentrations	concentrations	O	O	O	O
increased	increased	O	O	O	O
significantly	significantly	O	O	O	O
faster	faster	O	O	O	O
in	in	O	O	O	O
sgk1(-/-	sgk1(-/-	O	O	O	O
)	)	O	O	O	O
mice	mice	O	O	O	O
than	than	O	O	O	O
in	in	O	O	O	O
sgk1(+/+	sgk1(+/+	O	O	O	O
)	)	O	O	O	O
mice	mice	O	O	O	O
leading	leading	O	O	O	O
to	to	O	O	O	O
uremia	uremia	O	O	OTHERS	I
and	and	O	O	O	O
a	a	O	O	O	O
reduced	reduced	O	O	O	O
median	median	O	O	O	O
survival	survival	O	O	O	O
in	in	O	O	O	O
sgk1(-/-	sgk1(-/-	O	O	O	O
)	)	O	O	O	O
mice	mice	O	O	O	O
(	(	O	O	O	O
29	29	O	O	O	O
vs.	vs.	O	O	O	O
40	40	O	O	O	O
days	days	O	O	O	O
in	in	O	O	O	O
sgk1(+/+	sgk1(+/+	O	O	O	O
)	)	O	O	O	O
mice	mice	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
conclusion	conclusion	O	O	O	O
,	,	O	O	O	O
gene-targeted	gene-targeted	O	O	O	O
mice	mice	O	O	O	O
lacking	lacking	O	O	O	O
SGK1	sgk1	O	O	O	O
showed	showed	O	O	O	O
blunted	blunted	O	O	O	O
volume	volume	O	O	OTHERS	I
retention	retention	O	O	OTHERS	I
,	,	O	O	O	O
yet	yet	O	O	O	O
were	were	O	O	O	O
not	not	O	O	O	O
protected	protected	O	O	O	O
against	against	O	O	O	O
renal	renal	O	O	O	O
fibrosis	fibrosis	O	DISEASE	OTHERS	I
during	during	O	O	O	O
experimental	experimental	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

